Twenty-four patients with endometrial tumor tissue or mesenchymal cells with PD-L1 expression ≥ 1% in immunohistochemical staining participated in a phase Ib clinical trial (NCT 02054806), indicating that pembrolizumab has tolerable drug toxicity and is resistant to treatment. The gene discussed is CD274; the disease is endometrium neoplasm.